Fendiline

Identification

Name
Fendiline
Accession Number
DB08980
Type
Small Molecule
Groups
Withdrawn
Description

Fendiline is a coronary vasodilator which inhibits calcium function in muscle cells in excitation-contraction coupling. It has been proposed as an antiarrhythmic and antianginal agent. Fendiline is non-selective.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
S253D559A8
CAS number
13042-18-7
Weight
Average: 315.4513
Monoisotopic: 315.198699805
Chemical Formula
C23H25N
InChI Key
NMKSAYKQLCHXDK-UHFFFAOYSA-N
InChI
InChI=1S/C23H25N/c1-19(20-11-5-2-6-12-20)24-18-17-23(21-13-7-3-8-14-21)22-15-9-4-10-16-22/h2-16,19,23-24H,17-18H2,1H3
IUPAC Name
(3,3-diphenylpropyl)(1-phenylethyl)amine
SMILES
CC(NCCC(C1=CC=CC=C1)C1=CC=CC=C1)C1=CC=CC=C1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Fendiline.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Fendiline.Vet Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Fendiline.Approved, Investigational
AmobarbitalThe metabolism of Fendiline can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Fendiline.Approved, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Fendiline.Approved, Investigational
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Fendiline.Approved, Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Fendiline.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Fendiline is combined with Atorvastatin.Approved
AtosibanThe risk or severity of adverse effects can be increased when Fendiline is combined with Atosiban.Approved, Investigational
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Fendiline.Experimental
BarbexacloneThe metabolism of Fendiline can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Fendiline can be increased when combined with Barbital.Illicit
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Fendiline.Approved
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Fendiline.Approved, Investigational
Brefeldin AThe risk or severity of adverse effects can be increased when Brefeldin A is combined with Fendiline.Experimental
BucindololBucindolol may increase the hypotensive activities of Fendiline.Investigational
BunazosinBunazosin may increase the hypotensive activities of Fendiline.Investigational
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Fendiline.Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Fendiline.Approved
Calcium AcetateThe therapeutic efficacy of Fendiline can be decreased when used in combination with Calcium Acetate.Approved
Calcium CarbonateThe therapeutic efficacy of Fendiline can be decreased when used in combination with Calcium Carbonate.Approved
Calcium ChlorideThe therapeutic efficacy of Fendiline can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Fendiline can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Fendiline can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Fendiline can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Fendiline can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Fendiline can be decreased when used in combination with Calcium lactate.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Fendiline can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium laevulateThe therapeutic efficacy of Fendiline can be decreased when used in combination with Calcium laevulate.Experimental
Calcium pangamateThe therapeutic efficacy of Fendiline can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Fendiline can be decreased when used in combination with Calcium Phosphate.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Fendiline.Withdrawn
Capric acidThe risk or severity of adverse effects can be increased when Capric acid is combined with Fendiline.Experimental
CarbomycinThe metabolism of Fendiline can be decreased when combined with Carbomycin.Vet Approved
CarvedilolCarvedilol may increase the hypotensive activities of Fendiline.Approved, Investigational
CaseinThe therapeutic efficacy of Fendiline can be decreased when used in combination with Casein.Approved
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Fendiline.Approved
CerivastatinThe risk or severity of adverse effects can be increased when Fendiline is combined with Cerivastatin.Withdrawn
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Fendiline.Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Fendiline.Approved
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Fendiline.Approved, Investigational
CimetidineThe serum concentration of Fendiline can be increased when it is combined with Cimetidine.Approved
ClarithromycinThe metabolism of Fendiline can be decreased when combined with Clarithromycin.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Fendiline.Approved
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Fendiline.Approved, Vet Approved
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Fendiline.Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Fendiline.Approved, Investigational, Vet Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Fendiline.Investigational
DichloropheneThe risk or severity of adverse effects can be increased when Dichlorophene is combined with Fendiline.Vet Approved
DoxazosinDoxazosin may increase the hypotensive activities of Fendiline.Approved
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Fendiline.Approved
EfavirenzThe serum concentration of Fendiline can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Fendiline.Approved
ErythromycinThe metabolism of Fendiline can be decreased when combined with Erythromycin.Approved, Vet Approved
FenticonazoleThe risk or severity of adverse effects can be increased when Fenticonazole is combined with Fendiline.Experimental
FluconazoleThe serum concentration of Fendiline can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Fendiline.Approved
FlutrimazoleThe risk or severity of adverse effects can be increased when Flutrimazole is combined with Fendiline.Experimental
FluvastatinThe risk or severity of adverse effects can be increased when Fendiline is combined with Fluvastatin.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Fendiline.Approved
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Fendiline.Experimental
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Fendiline.Approved, Vet Approved
HachimycinThe risk or severity of adverse effects can be increased when Hachimycin is combined with Fendiline.Experimental
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Fendiline.Approved, Withdrawn
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Fendiline.Approved, Investigational
HexobarbitalThe metabolism of Fendiline can be increased when combined with Hexobarbital.Approved
IndoraminIndoramin may increase the hypotensive activities of Fendiline.Withdrawn
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Fendiline.Approved
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Fendiline.Approved, Investigational
JosamycinThe metabolism of Fendiline can be decreased when combined with Josamycin.Approved, Investigational
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Fendiline.Approved, Investigational
KitasamycinThe metabolism of Fendiline can be decreased when combined with Kitasamycin.Experimental
LabetalolLabetalol may increase the hypotensive activities of Fendiline.Approved
LovastatinThe risk or severity of adverse effects can be increased when Fendiline is combined with Lovastatin.Approved, Investigational
MepartricinThe risk or severity of adverse effects can be increased when Mepartricin is combined with Fendiline.Experimental
MethohexitalThe metabolism of Fendiline can be increased when combined with Methohexital.Approved
MethylphenobarbitalThe metabolism of Fendiline can be increased when combined with Methylphenobarbital.Approved
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Fendiline.Experimental
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Fendiline.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Fendiline.Approved, Investigational, Vet Approved
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Fendiline.Approved
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Fendiline.Vet Approved
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Fendiline.Experimental
NafcillinThe metabolism of Fendiline can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Fendiline.Approved
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Fendiline.Approved
NifuratelThe risk or severity of adverse effects can be increased when Nifuratel is combined with Fendiline.Experimental
Nikkomycin ZThe risk or severity of adverse effects can be increased when Nikkomycin Z is combined with Fendiline.Investigational
NitroprussideFendiline may increase the hypotensive activities of Nitroprusside.Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Fendiline.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Fendiline.Approved, Vet Approved
OleandomycinThe metabolism of Fendiline can be decreased when combined with Oleandomycin.Vet Approved
OmoconazoleThe risk or severity of adverse effects can be increased when Omoconazole is combined with Fendiline.Experimental
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Fendiline.Approved
PafuramidineThe risk or severity of adverse effects can be increased when Pafuramidine is combined with Fendiline.Investigational
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Fendiline.Approved
PentobarbitalThe metabolism of Fendiline can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe metabolism of Fendiline can be increased when combined with Phenobarbital.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Fendiline.Approved, Vet Approved
PitavastatinThe risk or severity of adverse effects can be increased when Fendiline is combined with Pitavastatin.Approved
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Fendiline.Approved, Investigational, Vet Approved
PravastatinThe risk or severity of adverse effects can be increased when Fendiline is combined with Pravastatin.Approved
PrazosinPrazosin may increase the hypotensive activities of Fendiline.Approved
PrimidoneThe metabolism of Fendiline can be increased when combined with Primidone.Approved, Vet Approved
PyrrolnitrinThe risk or severity of adverse effects can be increased when Pyrrolnitrin is combined with Fendiline.Experimental
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Fendiline.Experimental
RifabutinThe serum concentration of Fendiline can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Fendiline can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Fendiline can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Fendiline can be decreased when it is combined with Rifaximin.Approved, Investigational
RosuvastatinThe risk or severity of adverse effects can be increased when Fendiline is combined with Rosuvastatin.Approved
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Fendiline.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Fendiline.Approved, Vet Approved
SecobarbitalThe metabolism of Fendiline can be increased when combined with Secobarbital.Approved, Vet Approved
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Fendiline.Approved
SilodosinSilodosin may increase the hypotensive activities of Fendiline.Approved
SimvastatinThe risk or severity of adverse effects can be increased when Fendiline is combined with Simvastatin.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Fendiline.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Fendiline.Approved, Investigational
SolithromycinThe metabolism of Fendiline can be decreased when combined with Solithromycin.Investigational
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Fendiline.Approved
TamsulosinTamsulosin may increase the hypotensive activities of Fendiline.Approved, Investigational
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Fendiline.Approved
TelithromycinThe metabolism of Fendiline can be decreased when combined with Telithromycin.Approved
TerazosinTerazosin may increase the hypotensive activities of Fendiline.Approved
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Fendiline.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Fendiline.Approved
ThiamylalThe metabolism of Fendiline can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Fendiline can be increased when combined with Thiopental.Approved, Vet Approved
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Fendiline.Approved
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Fendiline.Approved
TolciclateThe risk or severity of adverse effects can be increased when Tolciclate is combined with Fendiline.Experimental
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Fendiline.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Fendiline.Experimental
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Fendiline.Approved, Investigational
TylosinThe metabolism of Fendiline can be decreased when combined with Tylosin.Vet Approved
UbidecarenoneThe risk or severity of adverse effects can be increased when Fendiline is combined with Ubidecarenone.Approved, Investigational, Nutraceutical
UrapidilUrapidil may increase the hypotensive activities of Fendiline.Investigational
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Fendiline.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

U.S. Patent 3,262,977.

General References
Not Available
External Links
KEGG Drug
D07185
PubChem Compound
3336
PubChem Substance
310264941
ChemSpider
3219
BindingDB
61401
ChEBI
94434
ChEMBL
CHEMBL254832
Wikipedia
fendiline
ATC Codes
C08EA01 — Fendiline

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)200-201U.S. Patent 3,262,977.
Predicted Properties
PropertyValueSource
Water Solubility6.22e-05 mg/mLALOGPS
logP5.63ALOGPS
logP5.83ChemAxon
logS-6.7ALOGPS
pKa (Strongest Basic)10.07ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area12.03 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity102.34 m3·mol-1ChemAxon
Polarizability37.62 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
Aralkylamines / Dialkylamines / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Diphenylmethane / Aralkylamine / Secondary amine / Secondary aliphatic amine / Organic nitrogen compound / Organopnictogen compound / Hydrocarbon derivative / Organonitrogen compound / Amine / Aromatic homomonocyclic compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Drug created on June 10, 2014 09:39 / Updated on December 01, 2017 16:11